Plasma homovanillic acid levels in temporal lobe epilepsy

Journal of Epilepsy

Volumn 11, Issue 6, 1998, Pages 383-388

  Fukuda, Masato ^a   Niwa, Shin Ichi ^b   Kumagai, Naoki ^c   Nagakubo, Shoji ^d   Hashimoto, Ohiko ^a   Shirayama, Yukihiko ^e   Hata, Akinobu ^a   Kameyama, Tomomichi ^f   Anzai, Nobuo ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c TOKYO METROPOLITAN MATSUZAWA HOSPITAL   (Japan)

^d Katsushikabashi Hospital   (Japan)

^e Department of Pharmacy   (Japan)

^f Dept of Obstetrics and Gynecology   (Japan)

Author keywords

Dopamine; Plasma homovanillic acid; Refractory seizure; Temporal lobe epilepsy

Indexed keywords

DOPAMINE; HOMOVANILLIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SEIZURE; TEMPORAL LOBE EPILEPSY;

EID: 0032210924     PISSN: 08966974     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0896-6974(98)00031-0     Document Type: Article

References (50)

1. 1. Hiramatsu M, Fujimoto N, Mori A. Catecholamine level in cerebrospinal fluid of epileptics. Neurochem Res 1982;7:1299-1305.
2. 2. Papeschi R, Molina-Negro P, Sourkes TL, Erba G. The concentration of homovanillic acid and 5-hydroxyindolacetic acids in ventricular and lumbar CSF. Neurology 1975;22:1151-9.
3. 3. Shaywitz BA, Cohen DJ, Bowers MB. Reduced cerebrospinal fluid 5-hydroxyindolacetic acid and homovanillic acid in children with epilepsy. Neurology 1975;25:72-79.
4. 4. Mori A, Hiramatsu M, Namba S, Nishimoto A, Ohmoto T, Mayanagi Y, Asakura T. Decreased dopamine level in epileptic focus. Res Commun Chem Pathol Pharmacol 1987;56:157-64.
5. 5. Shalev RS, Steinberg A, Lubetzki-Korn I, Amir N. Amantadine: Effective adjuvant therapy for intractable seizures. Neurology 1985;37(Suppl. 1):350.
6. 6. Shields WD, Lake JL, Chugani HT. Amantadine in the treatment of refractory epilepsy in childhood: An open trial in 10 patients. Neurology 1985;35:579-81.
7. 7. Leino E. Open trial with levodopa-carbidopa combination to patients with long standing progressive myoclonus epilepsy. Acta Neurol Scand 1981;63:389-94.
8. 8. Nakanishi S. Studies of monoamine therapy on epilepsy: The effects of L-DOPA, L-5HTP and bromocriptine on kindled convulsions and on epileptic patients. Fukushima Igaku Zasshi 1981;31:201-214 (in Japanese with English abstract).
9. 9. Ito M, Okuno T, Mikawa H. Brain monoamine metabolism and L-DOPA therapy for children with intractable epilepsy. Ann Paed Jpn 1982;28:32.
10. 10. Obeso JA, Artieda J, Tunon T, Luquin MR, Martinez Lage JM. Dopamine agonists suppress visual-cortical reflex myoclonus. J Neurol Neurosurg Psychiatry 1985;48:1277-83.
11. 11. Sperling MR, Pritchard III PB, Engel J Jr, Daniel C, Sagel J. Prolactin in partial epilepsy: An indicator of limbic seizures. Ann Neurol 1986;20:716-22.
12. 12. Yerby MS, van Belle G, Friel PN, Wilensky AJ. Serum prolactins in the diagnosis of epilepsy: Sensitivity, specificity, and predictive value. Neurology 1987;37:1224-6.
13. 13. Starr MS. The role of dopamine in epilepsy. Synapse 1996;22:159-94.
14. 14. Sutoo D, Akiyama K, Takita H. The relationship between metal ion levels and biogenic amine levels in epileptic mice. Brain Res 1987;418:205-13.
15. 15. Hevor TK, Aissi E, Delorme P. Correlation between carbohydrate and catecholamine level impairments in methionine sulfoximine epileptogenic rat brain. Neurochem Res 1990;15:861-8.
16. 16. Sutoo D, Akiyama K, Takita H. Effects of intraventricular administration of calcium on the lowering of brain dopamine level in epileptic mice. Epilepsy Res 1990;6:199-204.
17. 17. Suzuki S, Mori A. Regional distribution of tyrosine, tryptophan, and their metabolites in the brain of epileptic El mice. Neurochem Res 1992;17:693-8.
18. 18. Hara M, Sasa M, Serikawa T, Yamada T, Yamada J, Takaori S. Decreased dopamine and increased norepinephrine levels in the spontaneously epileptic rat, a double mutant rat. Epilepsia 1993;34:433-40.
19. 19. Tsuda H, Ito M, Oguro K, Mutoh K, Shiraishi H, Shirasaka Y, Mikawa H. Age-and seizure-related changes in noradrenaline and dopamine in several brain regions of epileptic El mice. Neurochem Res 1993;18:111-7.
20. 20. McKenzie GM, Soroko FE. The effects of apomorphine, (+)-amphetamine and L-dopa on maximal electroshock convulsions: A comparative study in the rat and mouse. J Pharm Pharmacol 1972;24:696-701.
21. 21. Kilian M, Frey HH. Central monoamines and convulsive thresholds in mice and rats. Neuropharmacology 1973;12:681-92.
22. 22. Anlezark GM, Meldrum BS. Effects of apomorphine, ergocornine and piribedil on audiogenic seizures in DBA/2 mice. Br J Pharmacol 1975;53:419-21.
23. 23. King GA, Burnham WM. Effects of d-amphetamine and apomorphine in a new animal model of petit mal epilepsy. Psychopharmacology 1980;69:281-5.
24. 24. La Grutta V, Sabatino M. Substantia nigra-mediated anticonvulsant action: A possible role of a dopaminergic component. Brain Res 1990;515:87-93.
25. 25. Ferraro G, Vella N, Sardo P, Caravaglios G, Sabatino M, La Grutta V. Dopaminergic control of feline hippocampal epilepsy: A nigrohippocampal pathway. Neurosci Lett 1991;123:41-44.
26. 2 dopamine receptors on the expression of motor seizures in mouse and rat. Neuropharmacology 1990;29:657-61.
27. 27. Barone P, Palma V, de Bartolomeis A, Cicarelli G, Campanella G. Dopaminergic regulation of epileptic activity. Neurochem Int 1992;20(Suppl):245S-9S.
28. 28. Loescher W, Czuczwar SJ. Studies on the involvement of dopamine D-1 and D-2 receptors in the anticonvulsant effect of dopamine agonists in various rodent models of epilepsy. Eur J Pharmacol 1986;128:55-65.
29. 2+-induced epileptiform activity in the rat cingulate cortex slice. NeuroReport 1993;5:78-80.
30. 30. van Ness PC, Olsen RW, Verity MA. MPTP is proconvulsant acutely but has no long-term effect in rodent models of seizure and epilepsy. Brain Res 1989;504:289-92.
31. 31. Lepore V, Di Reda N, Defacio G, Pedone D, Giovine A, Lanzi C, Tartaglione B, Livrea P. Dopaminomimetic action of diphenylhydantoin in rat striatum: Effect on homovanillic acid and cyclic AMP levels. Psychopharmacology 1985;86:27-30.
32. 32. Meshkibaf MH, Subhash MN, Madepalli Lakshmana K, Sridhara Rama Rao BS. Effect of chronic administration of phenytoin on regional monoamine levels in rat brain. Neurochem Res 1995;20:773-8.
33. 33. Barros HMT, Braz S, Leite JR. Effects of carbamazepine on dopamine release and reuptake in rat striatal slices. Epilepsia 1986;27:534-7.
34. 34. Amin F, Davidson M, Davis KL. Homovanillic acid measurement in clinical research: A review of methodology. Schizophr Bull 1992;18:123-48.
35. 35. Aizenstein ML, Korf J. Aspects of influx and efflux of homovanillic acid of rat cerebrospinal fluid. Brain Res 1978;149:129-40.
36. 36. Kalfakis N, Markianos M. Homovanillic acid and prolactin in plasma and CSF of medicated epileptic patients. Epilepsia 1987;28:138-41.
37. 37. Fukuda M, Niwa S-I, Kumagai N, et al. Compensatory function of central dopaminergic system for suppressing psychic seizures: Repeated plasma homovanillic acid measurement in refractory temporal lobe epilepsy. Epilepsy Res 1993;14:161-4.
38. 38. Garelis E, Sourkes TE. Use of cerebrospinal fluid drawn at pneumoencephalography in the study of monoamine metabolism in man. J Neurol Neurosurg Psychiatry 1974;37:704-10.
39. 39. Reynolds EH, Chadwick D, Jenner P, Chanarin I. Folate and monoamine metabolism in epilepsy. J Neurol Sci 1975;26:605-15.
40. 40. Laxer KD, Sourkes TL, Fang TY, Young SN, Gauthier SG, Missala K. Monoamine metabolites in the CSF of epileptic patients. Neurology 1979;29:1157-61.
41. 41. Habel A, Yates CM, McQueen JK, Blackwood D, Elton RA. Homovanillic acid and 5-hydroxyindolacetic acid in lumbar cerebrospinal fluid in children with afebrile and febrile convulsions. Neurology 1981;31:488-91.
42. 42. Silverstein F, Johnston MV. Cerebrospinal fluid monoamine metabolites in patients with infantile spasms. Neurology 1984;34:102-5.
43. 43. Markianos M, Kalfakis N. Neurotransmitter metabolites in medicated epileptic patients. Funct Neurol 1991;6:367-70.
44. 44. Devinsky O, Emoto S, Goldstein DS, Stull R, Porter RJ, Theodore WH, Nadi NS. Cerebrospinal fluid and serum levels of DOPA, catechols, and monoamine metabolites in patients with epilepsy. Epilepsia 1992;33:263-70.
45. 45. Walters DH, Walczak D. Cholinergic and dopaminergic involvement in phenobarbital-induced locomotor activity in mice. Neuropharmacology 1980;19:543-7.
46. 46. Friedhoff AJ. A dopamine-dependent restitutive system for the maintenance of mental normalcy. Ann NY Acad Sci 1986;463:47-52.
47. 47. Goldstein DS, Nadi NS, Stull R, Wyler AR, Porter R. Levels of catechols in epileptogenic and nonepileptogenic regions of the human brain. J Neurochem 1988;50:225-9.
48. 48. Mori A. Alterations in biogenic amines in epileptic El mouse brain and in human epileptic focus. In: Suzuki J, Seino M, Fukuyama Y, Komai S, eds. Art and science of epilepsy. Amsterdam: Elsevier Science Publishers BV, 1989:35-38.
49. 49. Louw D, Sutherland GR, Glavin GB, Girvin J. A study of monoamine metabolism in human epilepsy. Can J Neurol Sci 1989;16:394-7.
50. 50. Friedhoff AJ, Amin F, eds. Plasma homovanillic acid in schizophrenia: Implications for presynaptic dopamine dysfunction. Washington DC: American Psychiatric Press, Inc, 1997.